» Articles » PMID: 30267008

Control of Chronic Lymphocytic Leukemia Development by Clonally-expanded CD8 T-cells That Undergo Functional Exhaustion in Secondary Lymphoid Tissues

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2018 Sep 30
PMID 30267008
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic lymphocytic leukemia (CLL) is associated with substantial alterations in T-cell composition and function. However, the role of T-cells in CLL remains largely controversial. Here, we utilized the Eµ-TCL1 mouse model of CLL as well as blood and lymph node samples of CLL patients to investigate the existence of anti-tumoral immune responses in CLL, and to characterize involved immune cell populations. Thereby, we identified an oligoclonal CD8 effector T-cell population that expands along with CLL progression and controls disease development. We further show that a higher percentage of CD8 effector T-cells produces IFNγ, and demonstrate that neutralization of IFNγ results in faster CLL progression in mice. Phenotypical and functional analyses of expanded CD8 effector T-cells show significant differences in disease-affected tissues in mice, with cells in secondary lymphoid organs harboring hallmarks of activation-induced T-cell exhaustion. Notably, we further describe a respective population of exhausted CD8 T-cells that specifically accumulate in lymph nodes, but not in peripheral blood of CLL patients. Collectively, these data emphasize the non-redundant role of CD8 T-cells in suppressing CLL progression and highlight their dysfunction that can be exploited as target of immunotherapy in this malignancy.

Citing Articles

Immunophenotyping of Peripheral Blood Cells in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Stephan P, Bouherrou K, Guillermin Y, Michallet A, Grinberg-Bleyer Y Cells. 2024; 13(17.

PMID: 39273028 PMC: 11393851. DOI: 10.3390/cells13171458.


Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.

Derigs P, Schubert M, Dreger P, Schmitt A, Yousefian S, Haas S Leukemia. 2024; 38(11):2419-2428.

PMID: 39192036 PMC: 11519001. DOI: 10.1038/s41375-024-02392-7.


BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemia.

Smith A, Skupa S, Eiken A, Reznicek T, Schmitz E, Williams N JCI Insight. 2024; 9(10).

PMID: 38775157 PMC: 11141939. DOI: 10.1172/jci.insight.177054.


NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.

Bonato A, Chakraborty S, Bomben R, Canarutto G, Felician G, Martines C Leukemia. 2024; 38(7):1511-1521.

PMID: 38486128 PMC: 11216988. DOI: 10.1038/s41375-024-02224-8.


CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?.

Vitale C, Griggio V, Perutelli F, Coscia M Hemasphere. 2023; 7(12):e988.

PMID: 38044959 PMC: 10691795. DOI: 10.1097/HS9.0000000000000988.


References
1.
Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2009; 10(1):37-50. DOI: 10.1038/nrc2764. View

2.
Catovsky D, Miliani E, Okos A, GALTON D . Clinical significance of T-cells in chronic lymphocytic leukaemia. Lancet. 1974; 2(7883):751-2. DOI: 10.1016/s0140-6736(74)90944-1. View

3.
Forconi F, Moss P . Perturbation of the normal immune system in patients with CLL. Blood. 2015; 126(5):573-81. DOI: 10.1182/blood-2015-03-567388. View

4.
Pinon Hofbauer J, Heyder C, Denk U, Kocher T, Holler C, Trapin D . Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011; 25(9):1452-8. DOI: 10.1038/leu.2011.111. View

5.
Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View